Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Menu
Enjoy your FREE PREVIEW which shows only 2022 data and 25 documents. Contact Patent Forecast for full access.        

Z-ARCHIVE-Cannabis

Search All Applications in Z-ARCHIVE-Cannabis


Application US20190314296


Published 2019-10-17

Parenteral Formulations

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).



Much More than Average Length Specification


View the Patent Matrix® Diagram to Explore the Claim Relationships

USPTO Full Text Publication >

10 Independent Claims

  • 1. An aqueous parenteral formulation comprising: (i) a cannabinoid; (ii) an isotonic agent; (iii) a surfactant; and (iv) one or more stability enhancers.

  • 5. (canceled)

  • 9. (canceled)

  • 12. (canceled)

  • 16.-19. (canceled)

  • 22.-29. (canceled)

  • 32.-35. (canceled)

  • 37.-38. (canceled)

  • 40.-43. (canceled)

  • 46.-47. (canceled)